Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?

被引：57
作者：
Calvaruso, Vincenza [1 ]
Craxi, Antonio [1 ]
机构：
[1] Univ Palermo, Gastroenterol & Hepatol Unit, I-90127 Palermo, Italy
来源：
LIVER INTERNATIONAL | 2014年 / 34卷
关键词：
antiviral therapy; chronic hepatitis B; hepatocellular carcinoma; liver fibrosis; CHRONIC HEPATITIS-B; TENOFOVIR DISOPROXIL FUMARATE; VIRUS-RELATED CIRRHOSIS; ADEFOVIR DIPIVOXIL; HEPATOCELLULAR-CARCINOMA; INTERFERON THERAPY; NATURAL-HISTORY; LIVER-DISEASE; DECOMPENSATED CIRRHOSIS; COMPENSATED CIRRHOSIS;
D O I：
10.1111/liv.12395
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Long-lasting HBV-DNA suppression is considered to be the best surrogate end-point of antiviral therapy in patients with hepatitis B virus (HBV) related chronic hepatitis or cirrhosis, and it is a prerequisite to prevent liver-related complications and improve survival. Treatment with oral antiviral drugs in patients with HBV cirrhosis is effective in restoring liver function and improving survival even in those with decompensated cirrhosis. These agents are generally well-tolerated for long-term treatment, and several evidences have demonstrated that they are able to reverse liver fibrosis and prevent the occurrence of HCC.
引用
收藏
页码：85 / 90
页数：6
相关论文
共 49 条
  • [1] Brown A, 2012, EXPERT REV GASTROENT, V6, P187, DOI [10.1586/EGH.12.4, 10.1586/egh.12.4]
  • [2] Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
    Buster, Erik H. C. J.
    Hansen, Bettina E.
    Buti, Maria
    Delwaide, Jean
    Niederau, Claus
    Michielsen, Peter P.
    Flisiak, Robert
    Zondervan, Pieter E.
    Schalm, Solko W.
    Janssen, Harry L. A.
    [J]. HEPATOLOGY, 2007, 46 (02) : 388 - 394
  • [3] Fibrosis in chronic viral hepatitis
    Calvaruso, Vincenza
    Craxi, Antonio
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2011, 25 (02) : 219 - 230
  • [4] Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B
    Chang, Ting-Tsung
    Liaw, Yun-Fan
    Wu, Shun-Sheng
    Schiff, Eugene
    Han, Kwang-Hyub
    Lai, Ching-Lung
    Safadi, Rifaat
    Lee, Samuel S.
    Halota, Waldemar
    Goodman, Zachary
    Chi, Yun-Chan
    Zhang, Hui
    Hindes, Robert
    Iloeje, Uchenna
    Beebe, Suzanne
    Kreter, Bruce
    [J]. HEPATOLOGY, 2010, 52 (03) : 886 - 893
  • [5] Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    Chen, CJ
    Yang, HI
    Su, J
    Jen, CL
    You, SL
    Lu, SN
    Huang, GT
    Iloeje, UH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01): : 65 - 73
  • [6] Hepatitis B virus-related cirrhosis: Natural history and treatment
    Chu, CM
    Liaw, YF
    [J]. SEMINARS IN LIVER DISEASE, 2006, 26 (02) : 142 - 152
  • [7] THE NATURAL-HISTORY OF ASYMPTOMATIC HEPATITIS-B SURFACE-ANTIGEN CARRIERS
    DEFRANCHIS, R
    MEUCCI, G
    VECCHI, M
    TATARELLA, M
    COLOMBO, M
    DELNINNO, E
    RUMI, MG
    DONATO, MF
    RONCHI, G
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) : 191 - 194
  • [8] SURVIVAL AND PROGNOSTIC INDICATORS IN HEPATITIS-B SURFACE ANTIGEN-POSITIVE CIRRHOSIS OF THE LIVER
    DEJONGH, FE
    JANSSEN, HLA
    DEMAN, RA
    HOP, WCJ
    SCHALM, SW
    VANBLANKENSTEIN, M
    [J]. GASTROENTEROLOGY, 1992, 103 (05) : 1630 - 1635
  • [9] Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
    Di Marco, V
    Marzano, A
    Lampertico, P
    Andreone, P
    Santantonio, T
    Ahnasio, PL
    Rizzetto, M
    Craxì, A
    [J]. HEPATOLOGY, 2004, 40 (04) : 883 - 891
  • [10] Histological outcome during long-term lamivudine therapy
    Dienstag, JL
    Goldin, RD
    Heathcote, EJ
    Hann, HWL
    Woessner, M
    Stephenson, SL
    Gardner, S
    Gray, DF
    Schiff, ER
    [J]. GASTROENTEROLOGY, 2003, 124 (01) : 105 - 117
12345